• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

4-(邻苄基苯氧基)-N-甲基丁胺盐酸盐(MCI-2016,盐酸比芬美兰)的一般药理作用。对呼吸和心血管系统、肾功能、自主神经系统、离体平滑肌及消化器官的影响

[General pharmacological action of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016, bifemelane hydrochloride). Influence on respiratory and cardiovascular systems, renal function, autonomic nervous system, isolated smooth muscle and digestive organs].

作者信息

Narimatsu A, Nakao K, Ikoma H, Egawa M, Kitada Y, Yamazaki S, Umezu K, Miyake M, Nishimura E, Hashimoto N

出版信息

Nihon Yakurigaku Zasshi. 1986 Feb;87(2):223-51. doi: 10.1254/fpj.87.223.

DOI:10.1254/fpj.87.223
PMID:3754532
Abstract

MCI-2016 at 3 mg/kg, i.v., caused slight changes in systemic blood pressure (SBP), heart rate (HR), respiratory rate (RR) and ECG but at 10 mg/kg, i.v., it caused a significant increase in RR, decrease in SBP, increase or decrease in HR and a moderate change in ECG. Biphasic changes in SBP, HR and blood flow were sometimes observed after high doses. MCI-2016 also decreased SBP at 30 mg/kg, i.p., in SHR. MCI-2016 (50 mg/kg, p.o./day) showed little influence on SBP, HR and ECG in conscious beagle dogs. In isolated hearts, MCI-2016 decreased HR and contractility at the concentrations above 10(-5) g/ml, and 30 micrograms, i.a. MCI-2016 prolonged the AVCT at 10 mg/kg, i.v. MCI-2016 (i.v. or i.a.) moderately increased cerebral and femoral artery blood flows. MCI-2016 did not change CMRO2, but decreased MVO2. Coronary and renal artery flows were moderately increased by 10 mg/kg, i.v., of MCI-2016. Renal function was suppressed after 10 mg/kg, i.v., or 300 mg/kg, p.o., of MCI-2016. MCI-2016 potentiated the action of NE (increase in SBP, contractions of nictitating membrane and vas deferens), but showed little anti-cholinergic action. In contrast, MCI-2016 moderately increased gastrointestinal motility and salivatory response. As for the influence on isolated smooth muscles, MCI-2016 antagonized the contraction of blood vessels by high K+ at 10(-6) g/ml, or more, and it depressed the contractions by ACh, 5-HT, histamine and BaCl2 and also depressed spontaneous movements of uterus and ileum at 10(-5) M or more, in a nonspecific manner. MCI-2016 had no influence on liver damage and bile secretion, but inhibited stress ulcer and gastric acid secretion on the one hand, and caused gastric damage (125 mg/kg p.o., or more) on the other hand.

摘要

静脉注射3mg/kg的MCI - 2016会引起全身血压(SBP)、心率(HR)、呼吸频率(RR)和心电图的轻微变化,但静脉注射10mg/kg时,会导致RR显著增加、SBP降低、HR升高或降低以及心电图出现中度变化。高剂量给药后,有时会观察到SBP、HR和血流的双相变化。腹腔注射30mg/kg的MCI - 2016也会使自发性高血压大鼠(SHR)的SBP降低。口服(每天50mg/kg)的MCI - 2016对清醒的比格犬的SBP、HR和心电图影响较小。在离体心脏中,浓度高于10(-5)g/ml时,MCI - 2016会降低HR和收缩力,心室内注射30μg时也会出现这种情况。静脉注射10mg/kg的MCI - 2016会延长房室传导时间(AVCT)。静脉注射或心室内注射MCI - 2016会适度增加脑动脉和股动脉血流量。MCI - 2016不会改变脑代谢率(CMRO2),但会降低心肌耗氧量(MVO2)。静脉注射10mg/kg的MCI - 2016会适度增加冠状动脉和肾动脉血流量。静脉注射10mg/kg或口服300mg/kg的MCI - 2016后,肾功能会受到抑制。MCI - 2016增强了去甲肾上腺素(NE)的作用(SBP升高、瞬膜和输精管收缩),但抗胆碱作用较弱。相反,MCI - 2016会适度增加胃肠蠕动和唾液分泌反应。至于对离体平滑肌的影响,MCI - 2016在浓度为10(-6)g/ml或更高时可拮抗高钾引起的血管收缩,并且以非特异性方式抑制乙酰胆碱(ACh)、5 - 羟色胺(5 - HT)、组胺和氯化钡(BaCl2)引起的收缩,还会在浓度为10(-5)M或更高时抑制子宫和回肠的自发运动。MCI - 2016对肝损伤和胆汁分泌没有影响,但一方面抑制应激性溃疡和胃酸分泌,另一方面会导致胃损伤(口服125mg/kg或更高剂量)。

相似文献

1
[General pharmacological action of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016, bifemelane hydrochloride). Influence on respiratory and cardiovascular systems, renal function, autonomic nervous system, isolated smooth muscle and digestive organs].4-(邻苄基苯氧基)-N-甲基丁胺盐酸盐(MCI-2016,盐酸比芬美兰)的一般药理作用。对呼吸和心血管系统、肾功能、自主神经系统、离体平滑肌及消化器官的影响
Nihon Yakurigaku Zasshi. 1986 Feb;87(2):223-51. doi: 10.1254/fpj.87.223.
2
General pharmacology of recombinant human basic fibroblast growth factor.重组人碱性成纤维细胞生长因子的一般药理学
Arzneimittelforschung. 1996 Jul;46(7):727-39.
3
General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).人促肾上腺皮质激素释放激素(人源)的一般药理学特性。
Arzneimittelforschung. 1994 Jun;44(6):715-26.
4
General pharmacology of the new antimuscarinic compound vamicamide.新型抗毒蕈碱化合物瓦米卡胺的一般药理学
Arzneimittelforschung. 1995 Dec;45(12):1274-84.
5
General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.新型β-肾上腺素能受体拮抗剂卡维地洛的一般药理学特性
Arzneimittelforschung. 1990 Jul;40(7):735-46.
6
General pharmacological profile of the new cognition-enhancing agent nefiracetam.新型促认知药物奈非西坦的一般药理学特性
Arzneimittelforschung. 1994 Feb;44(2A):199-210.
7
[General pharmacology of T-3761, a new oral quinolone antibacterial agent (2). Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions].
Jpn J Antibiot. 1995 May;48(5):706-32.
8
General pharmacological properties of the new vasodilator flosequinan.新型血管扩张剂氟司喹南的一般药理学特性
Arzneimittelforschung. 1992 Oct;42(10):1200-11.
9
General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.新型抗血栓药物西洛他唑的一般药理学特性。第二部分:对周围器官的作用。
Arzneimittelforschung. 1985;35(7A):1163-72.
10
General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.新型血管紧张素转换酶抑制剂盐酸贝那普利的一般药理学。对心血管、内脏和肾功能以及血流动力学的影响。
Arzneimittelforschung. 1991 Sep;41(9):913-23.